Patents by Inventor Magali Hickey
Magali Hickey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220079939Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: ApplicationFiled: October 12, 2021Publication date: March 17, 2022Inventors: Philip CRESSWELL, Magali HICKEY, Kristopher PERKIN, Greg SMITH, Elaine LIVERSIDGE, Brian STEINBERG, David MANSER, Tarek ZEIDAN
-
Patent number: 11154552Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: GrantFiled: June 17, 2020Date of Patent: October 26, 2021Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip Cresswell, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Tarek Zeidan
-
Patent number: 10849894Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: GrantFiled: June 29, 2018Date of Patent: December 1, 2020Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip Cresswell, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Tarek Zeidan
-
Publication number: 20200316061Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (h) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: ApplicationFiled: June 17, 2020Publication date: October 8, 2020Inventors: Philip CRESSWELL, Magali HICKEY, Kristopher PERKIN, Greg SMITH, Elaine LIVERSIDGE, Brian STEINBERG, David MANSER, Tarek ZEIDAN
-
Patent number: 10688091Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: GrantFiled: May 20, 2019Date of Patent: June 23, 2020Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip Cresswell, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Tarek Zeidan
-
Publication number: 20190269676Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: ApplicationFiled: May 20, 2019Publication date: September 5, 2019Applicant: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip CRESSWELL, Magali HICKEY, Kristopher PERKIN, Greg SMITH, Elaine LIVERSIDGE, Brian STEINBERG, David MANSER, Tarek ZEIDAN
-
Patent number: 10159671Abstract: Described herein is a composition comprising: (a) a first population of particles of a first aripiprazole prodrug; and (b) a second population of particles of a second aripiprazole prodrug, different to the first aripiprazole prodrug. At least one of the first and second prodrug populations has a volume based particle size (Dv50) of less than about 1000 nm. Also described herein are methods of treatment using the aforementioned composition, and methods of making the aforementioned composition.Type: GrantFiled: February 16, 2017Date of Patent: December 25, 2018Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Tarek A. Zeidan, David Manser, Kristopher Perkin, Philip Cresswell, Magali Hickey, Brian Steinberg
-
Publication number: 20180318293Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: ApplicationFiled: June 29, 2018Publication date: November 8, 2018Applicant: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip Cresswell, Sara Montminy Paquette, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Ryan Turncliff, Michael Palmieri, JR., Tarek Zeidan, Ethan P. Cash, Marjie L. Hard
-
Patent number: 10016415Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilization of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: GrantFiled: August 17, 2015Date of Patent: July 10, 2018Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip Cresswell, Sara Montminy Paquette, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Ryan Turncliff, Michael Palmieri, Jr., Tarek Zeidan, Ethan P. Cash, Marjie L. Hard
-
Publication number: 20170231981Abstract: Described herein is a composition comprising: (a) a first population of particles of a first aripiprazole prodrug; and (b) a second population of particles of a second aripiprazole prodrug, different to the first aripiprazole prodrug. At least one of the first and second prodrug populations has a volume based particle size (Dv50) of less than about 1000 nm. Also described herein are methods of treatment using the aforementioned composition, and methods of making the aforementioned composition.Type: ApplicationFiled: February 16, 2017Publication date: August 17, 2017Applicant: ALKERMES PHARMA IRELAND LIMITEDInventors: Tarek A. ZEIDAN, David MANSER, Kristopher Perkin, Philip CRESSWELL, Magali HICKEY, Brian STEINBERG
-
Publication number: 20160045495Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.Type: ApplicationFiled: August 17, 2015Publication date: February 18, 2016Applicant: ALKERMES PHARMA IRELAND LIMITEDInventors: Philip CRESSWELL, Sara Montminy Paquette, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Ryan Turncliff, Michael Palmieri, Tarek Zeidan, Ethan P. Cash, Marjie L. Hard
-
Publication number: 20070021510Abstract: Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.Type: ApplicationFiled: September 4, 2004Publication date: January 25, 2007Applicant: Cephalon, Inc.Inventors: Magali Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
-
Publication number: 20060160783Abstract: The invention provides: (1) novel sodium-containing omeprazole salts formed by the reaction of omeprazole and a sodium source in a crystallization solvent; (2) novel zinc-containing omeprazole salts formed by the reaction of omeprazole and a zinc source in a crystallization solvent, including salts formed by the recrystallization of a zinc salt in a reaction mixture comprising a sodium-containing omeprazole salt and a crystallization solvent; and (3) methods of treatment which use the novel salts to treat or prevent gastric acid-related diseases.Type: ApplicationFiled: December 15, 2005Publication date: July 20, 2006Applicant: Transform Pharmaceuticals, Inc.Inventors: Magali Hickey, Matthew Peterson